- Home
- GERN vs NAGE Comparison
GERN vs NAGE Comparison
Compare GERN & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- NAGE
- Stock Information
- Founded
- GERN 1990
- NAGE 1999
- Country
- GERN United States
- NAGE United States
- Employees
- GERN 229
- NAGE N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- GERN Health Care
- NAGE Health Care
- Exchange
- GERN Nasdaq
- NAGE Nasdaq
- Market Cap
- GERN 823.0M
- NAGE 861.0M
- IPO Year
- GERN 1996
- NAGE N/A
- Fundamental
- Price
- GERN $1.30
- NAGE $9.82
- Analyst Decision
- GERN Buy
- NAGE Strong Buy
- Analyst Count
- GERN 8
- NAGE 3
- Target Price
- GERN $3.71
- NAGE $17.00
- AVG Volume (30 Days)
- GERN 6.6M
- NAGE 803.7K
- Earning Date
- GERN 11-06-2025
- NAGE 10-30-2025
- Dividend Yield
- GERN N/A
- NAGE N/A
- EPS Growth
- GERN N/A
- NAGE N/A
- EPS
- GERN N/A
- NAGE 0.22
- Revenue
- GERN $164,447,000.00
- NAGE $116,303,000.00
- Revenue This Year
- GERN $175.15
- NAGE $28.46
- Revenue Next Year
- GERN $56.61
- NAGE $21.65
- P/E Ratio
- GERN N/A
- NAGE $44.84
- Revenue Growth
- GERN 11877.20
- NAGE 35.90
- 52 Week Low
- GERN $1.09
- NAGE $3.16
- 52 Week High
- GERN $4.83
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- GERN 42.28
- NAGE 50.03
- Support Level
- GERN $1.27
- NAGE $9.16
- Resistance Level
- GERN $1.52
- NAGE $9.77
- Average True Range (ATR)
- GERN 0.06
- NAGE 0.38
- MACD
- GERN -0.02
- NAGE 0.03
- Stochastic Oscillator
- GERN 8.00
- NAGE 59.88
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.